Dr. Mario is a distinguished pharmaceutical executive. From 1989 to 1993, he served as Chief Executive of Glaxo, then the second-largest drug company in the world. After leaving Glaxo, he became Chairman and CEO of ALZA Corporation, a major drug delivery company sold to Johnson & Johnson for $10.5 Billion in 2001. Dr. Mario subsequently served as Chairman and CEO of Reliant Pharmaceuticals, which was sold to GlaxoSmithKline in 2007 for $1.65 Billion. He currently is Chairman and CEO of Capnia, a private pharmaceutical company developing novel therapeutic products to treat migraine and allergic rhinitis using a proprietary gas delivery system. He is also a Venture Partner with Pappas Ventures and serves on a number of corporate boards. Dr. Mario earned a B.S. in pharmacy at Rutgers and his M.S. and Ph.D. in physical sciences at the University of Rhode Island. He holds honorary doctorates from URI and Rutgers, the latter of which in 2001 renamed its pharmacy school the Ernest Mario School of Pharmacy. In 2007 he was awarded the Remington Medal by the American Pharmacists' Association, pharmacy's highest honor.
“It is a distinct privilege to welcome Dr. Mario to our board,” stated Richard Chin, M.D., Chief Executive Officer of Kindred Bio. “Dr. Mario brings a wealth of experience in pharmaceutical product development, drug delivery, and corporate strategy.”
“I look forward to working with the Kindred Bio team,” stated Dr. Mario. “The companion animal pharmaceutical market is a highly attractive and growing market, and Kindred Bio is well positioned to take the leadership in this field.
About Kindred Bio
“Best Medicines for Our Best Friends”
Kindred Bio is a leading veterinary biotechnology company, focused on developing breakthrough therapies for dogs, cats, and horses. Founded by industry veterans formerly from Genentech and Elan Pharmaceuticals who have experience developing antibody drugs such as Lucentis®, Tysabri®, Xolair®, and Rituxan®, Kindred Bio is committed to bringing the very best science and medicine to companion animals.
Forward Looking Statements
The inclusion of forward-looking statements in this news release should not be regarded as a representation that any of the company's plans or objectives will be achieved. Forward-looking statements involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in any such forward-looking statement. These factors include, but are not limited to uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and evolution of the companion animal market. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date.
Lucentis® is a registered trademarks of Genentech, Inc. Rituxan® is a registered trademark of Biogen Idec Inc. Xolair® is a registered trademark of Novartis AG Corporation. Tysabri® is a trademark of Elan Pharmaceuticals, Inc.